The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the absence of targeted mechanism-based therapies. As a result, it is difficult to provide adequate analgesia to all patients despite the extensive armamentarium of chronic pain therapies, including the increasing availability of cost-effective generic treatments. Indeed, the chronic pain therapy market is characterized by the high cost of pain management stemming from the long duration of treatment and from the many lines of therapy often required to maintain analgesic effects and by the increasing prevalence of key population segments, including osteoarthritis pain and chronic back pain. In recent years, the field has seen the emergence of abuse-deterrent formulations of opioid analgesics, which offer incremental advantages in safety and tolerability but struggle to compete against long-generic and firmly entrenched opioid analgesics as well as brand and generic nonopioid therapies.

Questions answered:

  • How is chronic pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
  • What impact have the more-recent launches of new brands such as Collegium Pharmaceutical’s Xtampza ER (oxycodone ER) and Iroko Pharmaceuticals’ Vivlodex (low-dose meloxicam) had on physician prescribing behavior for chronic pain?
  • What factors drive switching between or discontinuation of select analgesics?
  • How does the availability of abuse-deterrent opioid analgesic reformulations and branded nonopioid therapies impact physician prescribing of generic agents within the respective drug classes?

Product description:

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment: Physician Insights Chronic Pain US July 2019

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content. Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.


Related Reports

Chronic Pain | Landscape & Forecast | Disease Landscape & Forecast

Chronic pain’s highly crowded generics market makes gaining a strong foothold in the market challenging for branded agents. The treatment of chronic pain involves the use of drugs from seve...

View Details

Chronic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)

Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep...

View Details

Chronic Pain | Special Topics | Special Topics: How will Anti-NGF Therapies Disrupt Existing Pain Treatment Algorithms? (US)

The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanez...

View Details

Chronic Pain | Access & Reimbursement | Detailed, Expanded Analysis: Abuse-Deterrent Opioid Analgesics in Chronic Pain

Abuse-deterrent formulations (ADFs) of opioid analgesics entered the U.S. pain market in 2010 as an attempt to slow the increasing rates of abuse/...

View Details